A detailed history of 13 D Management LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, 13 D Management LLC holds 360,010 shares of EXEL stock, worth $9.34 Million. This represents 6.21% of its overall portfolio holdings.

Number of Shares
360,010
Previous 310,050 16.11%
Holding current value
$9.34 Million
Previous $7.36 Million 9.95%
% of portfolio
6.21%
Previous 4.64%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $1.02 Million - $1.19 Million
49,960 Added 16.11%
360,010 $8.09 Million
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $7,019 - $8,327
348 Added 0.11%
310,050 $7.36 Million
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $3.27 Million - $4.1 Million
-170,026 Reduced 35.44%
309,702 $7.43 Million
Q3 2023

Nov 14, 2023

BUY
$19.04 - $22.74 $2.39 Million - $2.86 Million
125,728 Added 35.52%
479,728 $10.5 Million
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $6.43 Million - $7.25 Million
354,000 New
354,000 $6.76 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.35B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track 13 D Management LLC Portfolio

Follow 13 D Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 13 D Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on 13 D Management LLC with notifications on news.